Full Press Release Details
linvoseltamab recommended for eu approval by the chmp to treat relapsed refractory multiple myeloma.
REGN
linvoseltamab recommended for eu approval by the chmp to treat relapsed refractory multiple myeloma
Key Takeaway: linvoseltamab recommended for eu approval by the chmp to treat relapsed refractory multiple myeloma